Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.
Cristina Saura, MD
Advertisement
Articles by Cristina Saura, MD
Advertisement
Latest Updated Articles
Effective Management and Prevention of Neratinib-Induced DiarrheaDecember 18th 2015
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates
5